Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

CAPFIMS to provide opportunity for medical graduates and specialists to serve in the medical cadre of CAPFs

The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.

GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme

SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties

Mastek partners King Faisal Specialist Hospital & Research Centre for healthcare transformation

The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client

Eversana partners with Compai Pharma to expand commercialisation services across APAC

EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners

HIL to commercialise VCRC Bti bio-larvicide technology for mosquito vector control programs

HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project

Dr. Reddy's to commercialise Tegoprazan in India and six emerging markets

HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales

Myovant Sciences and Accord Healthcare partner to commercialise Orgovyx in Europe

Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million

Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists

Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets